Punch: Preliminary results from a phase II study of intra-arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC).

被引：0
|
作者：
Wang, Zongren [1 ]
Zhan, Wenhao [1 ]
Huang, Bin [1 ]
Luo, Cheng [1 ]
Chen, Lingwu [1 ]
Chen, Junxing [1 ]
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
283-183-138-226-9326; 613-135-2370-7650-2454; 613-4678-146-11576; 613-135-244-3829; 6; 5; 4; 3; 2; 158; 2424; 1714; 76; 62; 1; 38092-20390; 38092-29187;
D O I：
10.1200/JCO.2024.42.4_suppl.618
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：618 / 618
页数：1
相关论文
共 50 条
  • [21] The Management of Bacillus Calmette-Guerin (BCG) Failure in High-Risk Non-muscle Invasive Bladder Cancer: A Review Article
    Kodera, Ahmed
    Mohammed, Mahmoud
    Lim, Paul
    Abdalla, Omer
    Elhadi, Mohammed
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (06)
  • [22] PEMBROLIZUMAB (PEMBRO) FOR PATIENTS (PTS) WITH HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (HR NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG): EFFICACY AND EVALUATION OF SUBSEQUENT CYSTECTOMY FROM COHORT B OF THE PHASE 2 KEYNOTE-057 STUDY
    Singer, Eric
    Necchi, Andrea
    Roumiguie, Mathieu
    Esen, Ahmet Adil
    Lebret, Thierry
    de Wit, Ronald
    Bajorin, Dean F.
    Krieger, Laurence E. M.
    Kandori, Shuya
    Uchio, Edward M.
    Seo, Ho Kyung
    Boormans, Joost
    Kamat, Ashish M.
    Grivas, Petros
    Nishiyama, Hiroyuki
    Baranwal, Pranshu
    Kapadia, Ekta
    Van den Sigtenhorst-Fijlstra, Margot
    Kulkarni, Girish S.
    Shore, Neal D.
    JOURNAL OF UROLOGY, 2023, 209 : E1195 - E1195
  • [23] A phase 3, randomized, open-label, multicenter, global study of Durvalumab and bacillus calmette-Guerin (BCG) vs BCG alone in high-risk, BCG-naive non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC)
    Boegemann, M.
    Abdrashitov, R.
    Casuscelli, J.
    Feyerabend, S.
    Hatiboglu, G.
    Hegele, A.
    Hellmis, E.
    Klier, J.
    von Klot, C.
    Schmitz-Draeger, B.
    Spiegelhalder, P.
    Stagge, E.
    De Santis, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 105 - 105
  • [24] A phase Ill, randomized, open-label, multicenter, global study of durvalumab and bacillus calmette-guerin (BCG) versus BCG alone in high-risk, BCG-naive non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC).
    De Santis, Maria
    Abdrashitov, Ramil
    Hegele, Axel
    Kolb, Margaret
    Parker, Suzanne
    Redorta, Juan Palou
    Nishiyama, Hiroyuki
    Xiao, Feng
    Gupta, Ashok Kumar
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [25] Theories behind Bacillus Calmette-Guerin failure in high-risk non-muscle-invasive bladder cancer and update on current management
    Maroof, Hanna
    Paramore, Louise
    Ali, Ahmed
    CANCER PATHOGENESIS AND THERAPY, 2024, 2 (02): : 74 - 80
  • [26] Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette-Guerin (BCG) unresponsive, high-risk (HR) non-muscle-invasive bladder cancer (NMIBC): Over two years follow-up of KEYNOTE-057.
    Balar, Arjun Vasant
    Kamat, Ashish M.
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Bajorin, Dean F.
    Roumigui, Mathieu
    Singer, Eric A.
    Krieger, Laurence Eliot Miles
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Zambon, Joao Paulo
    Kapadia, Ekta
    De Wit, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Atezolizumab plus intravesical BCG (Bacillus Calmette-Guerin) in high-risk non-muscle invasive bladder cancer (NMIBC) patients: Institutional clinical and translational study (BladderGATE)
    Castellano, Daniel
    de Velasco, Guillermo
    Martin Soberon, Maria Cruz
    Carretero-Gonzalez, Alberto
    Duenas, Marta
    Paramio, Jesus
    De la Rosa, Federico
    Luis Sanz, Juan
    Guerrero, Felix
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [28] Predicting response to bacillus Calmette-Guerin in high-risk non-muscle invasive bladder cancer
    Soltani-Tehrani, Amir M.
    Kumar, Aman
    Pohar, Kamal S.
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (11) : 6489 - 6502
  • [29] Intra-arterial chemotherapy combined with BCG immunotherapy is more effective than intra-arterial chemotherapy plus intravesical chemotherapy or standard BCG immunotherapy in preventing the recurrence and progression of high-risk non-muscle-invasive bladder cancer
    Luo, Shuhang
    Wu, Yukun
    Yang, Rui
    Liu, Jinwen
    Wusimanjiang, Wumier
    Zhan, Wenhao
    Si, Enyou
    Chen, Lingwu
    Lin, Hao
    Chen, Junxing
    Huang, Bin
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 (12) : 450e1 - 450e12
  • [30] Urinary cytokine profiles reflect rationale for treatment with gemcitabine and Bacillus Calmette-Guerin (BCG) in BCG-exposed high-risk non-muscle invasive bladder cancer (NMIBC)
    Gaffney, Christopher D.
    Alam, Syed M.
    Lavery, Jessica A.
    Basar, Merve
    D'Souza, Neeta
    Hernandez, Christian
    McCarter, Melissa
    Moran, Patricia
    Stasi, Kristen
    Worth, Kara
    Sjoberg, Daniel
    Dalbagni, Guido
    Donahue, Timothy
    Donat, Sherri
    Bajorin, Dean
    Bochner, Bernard H.
    Goh, Alvin
    Sarungbam, Judy
    Al-Ahmadie, Hikmat
    Pietzak, Eugene J.
    CLINICAL CANCER RESEARCH, 2024, 30 (10)
12345